Skip to Content

Eucrisa Approval History

FDA Approved: Yes (First approved December 14, 2016)
Brand name: Eucrisa
Generic name: crisaborole
Dosage form: Topical Ointment
Company: Pfizer Inc.
Treatment for: Atopic Dermatitis

Eucrisa (crisaborole) is a novel, non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor indicated for the treatment of mild-to-moderate atopic dermatitis.

Development History and FDA Approval Process for Eucrisa

DateArticle
Dec 14, 2016Approval FDA Approves Eucrisa (crisaborole) for Eczema
Jul 13, 2016Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis
Mar 22, 2016Anacor Pharmaceuticals Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis
Jan  7, 2016Anacor Pharmaceuticals Submits NDA to the FDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide